Literature DB >> 1387484

The effect of paroxetine on anxiety and agitation associated with depression.

D Sheehan1, G C Dunbar, D L Fuell.   

Abstract

To assess the effects of treatment on symptoms of anxiety and agitation associated with depression, a data base of 2963 paroxetine treated patients was compared with 554 who received placebo and 1151 on active control. Paroxetine and active control both reduced baseline psychic anxiety more effectively than placebo. Both pharmacological treatments were effective in treating somatic anxiety with active control demonstrating an earlier onset of activity. Neither paroxetine nor active control induced new anxiety symptoms. Paroxetine was superior to placebo in the treatment of agitation at Weeks 4 and 6 and to active control at Week 4 only. Both paroxetine and active control were more protective against emergent (new) agitation than placebo. There was no difference between the three groups in the incidence of spontaneously reported adverse events indicative of anxiety.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387484

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  5 in total

Review 1.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 2.  Paroxetine: an update of its use in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

4.  Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment.

Authors:  Alan J. Gelenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-04

Review 5.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.